학술논문

Impact of multiple substance use on circulating ST2, a biomarker of adverse cardiac remodelling, in women
Document Type
article
Source
Biomarkers. 27(8)
Subject
Medical Biotechnology
Biomedical and Clinical Sciences
Prevention
Heart Disease
Cardiovascular
Substance Misuse
Detection
screening and diagnosis
4.1 Discovery and preclinical testing of markers and technologies
Good Health and Well Being
Female
Humans
Middle Aged
Interleukin-1 Receptor-Like 1 Protein
Ventricular Remodeling
Heroin
Ethnicity
Minority Groups
Biomarkers
Heart Failure
Cardiovascular Diseases
Substance-Related Disorders
Prognosis
ST2
substance use
cardiac remodelling
women
Environmental Biotechnology
Toxicology
Bioinformatics and computational biology
Medical biotechnology
Environmental biotechnology
Language
Abstract
ContextCardiovascular disease (CVD) and heart failure (HF) are major causes of mortality in low-income populations and differ by sex. Risk assessment that incorporates cardiac biomarkers is common. However, research evaluating the utility of biomarkers rarely includes controlled substances, which may influence biomarker levels and thus influence CVD risk assessment.Materials and methodsWe identified the effects of multiple substances on soluble "suppression of tumorigenicity 2" (sST2), a biomarker of adverse cardiac remodelling, in 245 low-income women. Adjusting for CVD risk factors, we examined associations between substance use and sST2 over six monthly visits.ResultsMedian age was 53 years and 74% of participants were ethnic minority women. An sST2 level > 35 ng/mL (suggesting cardiac remodelling) during ≥1 study visit was observed in 44% of participants. In adjusted analysis, higher sST2 levels were significantly and positively associated with the presence of cocaine (Adjusted Linear Effect [ALE]:1.10; 95% CI:1.03-1.19), alcohol (ALE:1.10; 95% CI:1.04-1.17), heroin (ALE:1.25; 95% CI:1.10-1.43), and the interaction between heroin and fentanyl use.ConclusionResults suggest that the use of multiple substances influences the level of sST2, a biomarker often used to evaluate cardiovascular risk. Incorporating substance use alongside cardiac biomarkers may improve CVD risk assessment in vulnerable women.